The Compounding Power of Outliers | Ep. 976

How US VC Exits Are Evolving

Hello Avatar! Welcome back for another week of biotech analysis. Today is Sunday, which means this is our Building Biotech newsletter that is focused on discussing biopharma strategy topics. This week, we’re diving into the economics of gene therapy—the risks, rewards, and what needs to happen for this model to survive. We’ll break down the shift from l…